By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Lifestyle UgandaLifestyle Uganda
  • Home
  • News
    • International News & Politics
    • Education
    • Sports
    • Money & Finance
    • Mobile and Telecommunication
    News
    Lifestyle Uganda brings you the latest news and information on Africa, Wizkid, Azawi, and Eddy Kenzo right from the heart of the industry.
    Show More
    Top News
    Lycamobile Uganda data bundles and voice (1)
    Lycamobile Uganda: 4 Most Frequently Asked Questions & Answers
    5th November 2021
    Who is John Blaq: Biography, Profile and Life Story of Kashada John
    Who is John Blaq: Biography, Profile and Life Story of Kashada John
    19th September 2020
    lifestyleug.com__Airtel Uganda revises its double data bundle offers (1)
    Airtel Uganda Is Now Offering Double Data Bundles for Its Smartphone Users
    Sponsored by Chipper CashChipper Cash
    Latest News
    $10,000 Donated by Exness to Help 2022 Nigerian Flood Victims
    20th January 2023
    Former Brazilian Minister of Sports Pele Died at the Age of 82
    30th December 2022
    37 Visa Exempt Countries to Uganda: A Complete List
    7th December 2022
    Who is Patrick Oboi Amuriat: Biography, Early Life, Family, Education, Career and Controversies
    28th November 2022
  • Business
  • Entertainment
    • Music
    • Celebrity
    • Biography
    • Lifestyle
      • Fitness
      • Pop Culture
      • Recipes
      • Travel/Culture
    Entertainment
    With Lifestyle Uganda Entertainment you will be able to get the latest news from Uganda, Nigeria, Kenya, South Africa entertainment, celebrity gossip, films, TV shows,…
    Show More
    Top News
    Lycamobile Uganda data bundles and voice (1)
    Lycamobile Uganda: 4 Most Frequently Asked Questions & Answers
    5th November 2021
    Who is John Blaq: Biography, Profile and Life Story of Kashada John
    Who is John Blaq: Biography, Profile and Life Story of Kashada John
    19th September 2020
    Bobi Wine and Barbie Share First Joint Magazine Cover
    Bobi Wine and Barbie Share First Joint Cover on Parents Magazine in Kenya
    3rd November 2018
    Latest News
    Nominations for the 2023 Oscars: Tems Nominated for Lift Me Up
    25th January 2023
    London’s Tottenham Hotspur Stadium to Host Massive Wizkid Show
    24th January 2023
    Tickets, Lineup, and Dates for Afro Nation Portugal 2023
    23rd January 2023
    Winners of the All Africa Music Awards 2022/2023: Burna Boy, Davido
    21st January 2023
  • Fashion
    • Beauty Trends
    • Accessories
    • Hair
    • Lipstick
    • Makeup
    • Skincare
    FashionShow More
    lifestyleuganda.com__Fenty Beauty appoints Nikita Kering as brand ambassador (1)
    Rihanna’s Fenty Beauty Appoints Nikita Kering As Brand Ambassador
    1st June 2022
    nowthendigital.com__Balenciaga to accept cryptocurrency payments (1)
    Fashion Label Balenciaga to Accept Cryptocurrency Payments in the U.S.
    28th May 2022
    Nicki Minaj at met gala 2022 (1)
    See Nicki Minaj, Hillary Clinton, Elon Musk, Alicia Keys and More at the 2022 Met Gala
    3rd May 2022
    lifestyleuganda.com-Judith Heard wins Miss Environment Africa International
    Judith Heard wins Miss Environment Africa International in India
    4th April 2022
    lifestyleuganda.com__judith heard india miss environment contest (1)
    Miss Environment International 2022: Judith Heard arrives in India
    22nd March 2022
  • Health & Living
  • Tips & Advice
Search
© 2023 Lifestyle Uganda. All Rights Reserved.
Reading: BioNTech and Pfizer Says COVID-19 Vaccine Is 90-per Cent Effective
Share
Sign In
Notification Show More
Latest News
ashwagandha benefits
Ashwagandha: What Is It and How Does It Work?
Health & Living
Tems at 2023 Oscar nominations
Nominations for the 2023 Oscars: Tems Nominated for Lift Me Up
Entertainment Music
Wizkid announces London Date 29th July 2023
London’s Tottenham Hotspur Stadium to Host Massive Wizkid Show
Entertainment Music
burna boy afro nation 2023
Tickets, Lineup, and Dates for Afro Nation Portugal 2023
Entertainment Music
burna boy all africa music awards 2022 winners
Winners of the All Africa Music Awards 2022/2023: Burna Boy, Davido
Entertainment Music
Aa
Lifestyle UgandaLifestyle Uganda
Aa
  • Home
  • News
  • Business
  • Entertainment
  • Health & Living
Search
  • Home
  • News
    • International News & Politics
    • Education
    • Sports
    • Money & Finance
    • Mobile and Telecommunication
  • Business
  • Entertainment
    • Music
    • Celebrity
    • Biography
    • Lifestyle
  • Fashion
    • Beauty Trends
    • Accessories
    • Hair
    • Lipstick
    • Makeup
    • Skincare
  • Health & Living
  • Tips & Advice
Have an existing account? Sign In
Follow US
© 2023 Lifestyle Uganda. A Now & Entertainment Media Company. All Rights Reserved.
Lifestyle Uganda > Blog > Health & Living > BioNTech and Pfizer Says COVID-19 Vaccine Is 90-per Cent Effective
Health & LivingNews

BioNTech and Pfizer Says COVID-19 Vaccine Is 90-per Cent Effective

Musasi Isaac Christopher
Last updated: 2020/11/10 at 12:22 AM
Musasi Isaac Christopher
Share
9 Min Read
lifestyleug.com__biontech pfizer covid-19 vaccine
According to BioNTech and Pfizer, the results of the first set of Phase 3 COVID-19 vaccine tests provide early evidence that the vaccine has the 90-per cent potential to cure the infection. PHOTO via @Pfizer
SHARE

BioNTech says the first interim analysis of the Global Phase 3 Study shows that COVID-19 can be effectively prevented by the vaccine.

lifestyleug.com__biontech pfizer covid-19 vaccine
According to BioNTech and Pfizer, the results of the first set of Phase 3 COVID-19 vaccine tests provide early evidence that the vaccine has the 90-per cent potential to cure the infection. PHOTO via @Pfizer

BioNTech, a German company that collaborates with Pfizer from the United States, has announced its progress in obtaining the COVID-19 vaccine.

Pfizer chairman Dr Albert Bourla said the results of the first set of Phase 3 COVID-19 vaccine trials provide early evidence that the vaccine has the potential to cure infections.

“Today is a great day for science and humanity. The results of the first set of our Phase 3 COVID-19 vaccine test provide early evidence of our vaccine’s ability to prevent COVID – 19, ”reads an excerpt from Dr Albert’s report.

He said with new records for epidemics, high-capacity hospitals and economies struggling to reopen, they are reaching an important milestone in developing the vaccine against the epidemic at a time when the world is most in need.

- Advertisement -

“With today’s news, we are an important step in delivering much needed improvements to people around the world to help put an end to this global health crisis. We look forward to sharing additional performance and safety data generated from thousands of participants. In the coming weeks.”

Meanwhile, the third phase of clinical trials of BNT162b2 began on July 27 and registered 43,538 participants, 38,955 of whom received the second dose of the vaccine candidate until November 8, 2020.

According to Professor Ugur Sahin, co-founder and CEO of BioNTech, the first interim analysis of the Global Phase 3 study provides evidence that the vaccine can effectively prevent COVID-19.

“The first interim analysis of our Global Phase 3 study provides evidence that a vaccine can effectively inhibit COVID-19. It is a breakthrough in innovation, science and global collaboration,” he said.

This comes at a time when the coronavirus continues to rise worldwide with confirmed cases hitting 50,891,706 by Monday afternoon. Of these, a total of 35,879,529 have recovered from the virus and 1,264,205 have been infected.

SEE ALSO  Protesters Turn Violent After Police Shot an Unarmed Black Man, Jacob Blake

- Advertisement -

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr Albert Bourla, Pfizer Chairman and CEO. 

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. 

- Advertisement -

With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases.

Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. 

The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. 

SEE ALSO  Moringa Benefits For Hair and Skin

“We could not have come this far without the tremendous commitment of everyone involved.”

The new covid vaccine BNT162b2

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO.

“When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. 

We will continue to collect further data as the trial continues to enrol for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to making this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. 

Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds.

The trial is continuing to enrol and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.

The study also will evaluate the potential for the vaccine candidate to protect COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease.

In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well.

SEE ALSO  FDA: The US is the Latest Country to Approve Pfizer COVID-19 Vaccine

The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. 

Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.

Based on current projections they expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • More
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Tumblr (Opens in new window)

Related

You Might Also Like

Nominations for the 2023 Oscars: Tems Nominated for Lift Me Up

London’s Tottenham Hotspur Stadium to Host Massive Wizkid Show

Tickets, Lineup, and Dates for Afro Nation Portugal 2023

Winners of the All Africa Music Awards 2022/2023: Burna Boy, Davido

BRIT Awards 2023 nominated Burna Boy and Fireboy DML

TAGGED: biontech covid-19 vaccine, biontech pfizer covid-19 vaccine, biontech vaccine 90-per cent effective, covid-19 vaccine, covid-19 vaccine 90-per cent, covid-19 vaccine 90-per cent effective, effective biontech pfizer covid-19, effective biontech pfizer results, pfizer covid-19 vaccine, pfizer covid-19 vaccine effective, pfizer vaccine 90-per cent effective, phase 3 covid-19 vaccine

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
I have read and agree to the terms & conditions
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Musasi Isaac Christopher 10th November 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Reddit Copy Link
Share
By Musasi Isaac Christopher
Follow:
An aspiring Lifestyle blogger who specializes in health, food and restaurant sectors. WhatsApp me on +256759100143.
Previous Article lifestyleug.com__mtn uganda cuts withdrawal rates MTN Uganda Cuts Withdrawal Rates on Its Mobile Money Service
Next Article lifestyleug.com__trt world phase 3 covid-19 vaccine (2) The first set of Phase 3 COVID-19 vaccine Is 90-per Cent Effective
Leave a comment Leave a comment

Leave a Reply Cancel reply

Stay Connected

45.2k Followers Like
5.1k Followers Follow
213 Followers Pin
35.6k Followers Follow
11k Subscribers Subscribe
400 Followers Follow
- Advertisement -

Latest News

ashwagandha benefits
Ashwagandha: What Is It and How Does It Work?
Health & Living 25th January 2023
Tems at 2023 Oscar nominations
Nominations for the 2023 Oscars: Tems Nominated for Lift Me Up
Entertainment Music 25th January 2023
Wizkid announces London Date 29th July 2023
London’s Tottenham Hotspur Stadium to Host Massive Wizkid Show
Entertainment Music 24th January 2023
burna boy afro nation 2023
Tickets, Lineup, and Dates for Afro Nation Portugal 2023
Entertainment Music 23rd January 2023

Follow Us

//

At Lifestyle Uganda, we inform, entertain, and inspire action through the content we create — empowering you to live a celebrity life.

Quick Link

  • Home
  • News
  • Business
  • Entertainment
  • Health & Living

Top Categories

  • About Us
  • Send a Tip
  • Terms of Use
  • Privacy Policy
  • Contact

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

I have read and agree to the terms & conditions
Lifestyle UgandaLifestyle Uganda
Follow US

© 2023 Lifestyle Uganda. A Now & Entertainment Media Company. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
 

Loading Comments...
 

    Welcome Back!

    Sign in to your account

    Lost your password?